Somatostatin receptor scintigraphy (SRS) is a very valuable imaging technique for visualisation of a diversity of neuroendocrine tumours. The sensitivity for localisation of carcinoid tumours is high, but somewhat lower for other neuroendocrine tumours. The methodology, multiple clinical aspects and limitations of the examination are described. The value of the method in patients with non-neuroendocrine tumours has yet to be established. The development of new radio-labelled somatostatin analogues for diagnosis and treatment is briefly discussed.
Ugeskrift for Laeger, 2005, Vol 167, Issue 49, p. 4647-4650